FDA officials are looking toward a future where sponsors will be asked to do more to avoid clinical trial dropouts that lead to missing data, including doing a better job at retaining patients and implementing procedures to follow up on those patients.
During the Sept. 10 advisory committee for GlaxoSmithKline PLC’s combination COPD treatment Anoro Ellipta, missing data, caused largely by high study withdrawal rates and subsequent lack of follow up,...